QualityStocksNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Plans Phase 3 MDMA-Assisted Therapy Trial for PTSD
This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced plans to initiate a Health Canada-authorized Phase 3 clinical trial in 2027 evaluating MDMA-assisted therapy for post-traumatic stress disorder (“PTSD”). The trial is intended to enroll up to 100 participants across multiple Canadian sites, focusing on veterans and current or former frontline workers, including military personnel, police, paramedics, firefighters and healthcare workers. Participants will receive Optimi’s synthetic MDMA HCl during two supervised sessions combining MDMA and psychotherapy, with the primary efficacy endpoint measuring changes in…